|
Market Closed -
Nasdaq
21:00:00 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 37.00 USD | -2.17% |
|
-0.19% | +20.13% |
| 10-16 | Nordic stocks in North America - Ericsson rose 2.6 percent | FW |
| 10-15 | Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug | RE |
Company Valuation: Genmab A/S
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 172,063 | 192,229 | 140,770 | 94,810 | 124,862 | 149,505 | - | - |
| Change | - | 11.72% | -26.77% | -32.65% | 31.7% | 19.74% | - | - |
| Enterprise Value (EV) 1 | 152,725 | 169,905 | 112,635 | 73,709 | 114,029 | 169,171 | 160,943 | 147,390 |
| Change | - | 11.25% | -33.71% | -34.56% | 54.7% | 48.36% | -4.86% | -8.42% |
| P/E | 57.8x | 35.2x | 32.6x | 12.3x | 20.9x | 30.7x | 21.8x | 14.5x |
| PBR | 7.82x | 7.07x | 4.5x | 2.68x | 3.47x | 3.64x | 3.11x | 2.58x |
| PEG | - | 0.4x | -1.5x | 0.1x | -1x | -1.9x | 0.5x | 0.3x |
| Capitalization / Revenue | 20.3x | 13.2x | 8.54x | 4.4x | 5.31x | 5.03x | 4.27x | 3.41x |
| EV / Revenue | 18x | 11.6x | 6.84x | 3.42x | 4.85x | 5.69x | 4.6x | 3.36x |
| EV / EBITDA | 46.8x | 25.3x | 20.1x | 10.4x | 15.9x | 19.1x | 13x | 8.51x |
| EV / EBIT | 50.6x | 26.7x | 21.2x | 10.5x | 17x | 21.4x | 15.5x | 9.91x |
| EV / FCF | 77.3x | 47.3x | 16.1x | 9.72x | 15.7x | 27.8x | 21x | 12.4x |
| FCF Yield | 1.29% | 2.12% | 6.23% | 10.3% | 6.36% | 3.59% | 4.77% | 8.05% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 45.54 | 83.65 | 66.02 | 121.4 | 97.08 | 81.38 | 114.9 | 173 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8,482 | 14,595 | 16,474 | 21,526 | 23,497 | 29,718 | 35,019 | 43,854 |
| EBITDA 1 | 3,266 | 6,719 | 5,616 | 7,116 | 7,175 | 8,863 | 12,364 | 17,311 |
| EBIT 1 | 3,018 | 6,357 | 5,321 | 7,003 | 6,727 | 7,892 | 10,352 | 14,879 |
| Net income 1 | 3,008 | 5,522 | 4,352 | 7,844 | 6,083 | 5,020 | 7,289 | 11,412 |
| Net Debt 1 | -19,338 | -22,324 | -28,135 | -21,101 | -10,833 | 19,666 | 11,438 | -2,115 |
| Reference price 2 | 2,630.00 | 2,941.00 | 2,155.00 | 1,492.50 | 2,027.00 | 2,502.00 | 2,502.00 | 2,502.00 |
| Nbr of stocks (in thousands) | 65,423 | 65,362 | 65,322 | 63,524 | 61,599 | 59,754 | - | - |
| Announcement Date | 16/02/22 | 22/02/23 | 14/02/24 | 12/02/25 | 17/02/26 | - | - | - |
1DKK in Million2DKK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 26.11x | 26.57x | 15.32x | 0.32% | 41.37B | |
| Weighted average by Cap. | 25.97x | 25.01x | 15.48x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Valuation Genmab A/S
Select your edition
All financial news and data tailored to specific country editions
